Literature DB >> 8799518

Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions.

D A Barrett1, D P Barker, N Rutter, M Pawula, P N Shaw.   

Abstract

1. The pharmacokinetics of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) were studied in 19 ventilated newborn infants (24-41 weeks gestation) who were given a loading dose of 50 micrograms kg-1 or 200 micrograms kg-1 of diamorphine followed by an intravenous infusion of 15 micrograms kg-1 h-1 of diamorphine. Plasma concentrations of morphine, M3G and M6G were measured during the accrual to steady-state and at steady state of the diamorphine infusion. 2. Following both the 50 micrograms kg-1 or 200 micrograms kg-1 loading doses the mean steady-state plasma concentration (+/- s.d.) of morphine, M3G and M6G were 86 +/- 52 ng ml-1, 703 +/- 400 ng ml-1 and 48 +/- 28 ng ml-1 respectively and morphine clearance was found to be 4.6 +/- 3.2 ml min-1 kg-1. 3. M3G formation clearance was estimated to be 2.5 +/- 1.8 ml min-1 kg-1, and the formation clearance of M6G was estimated to be 0.46 +/- 0.32 ml min-1 kg-1. 4. M3G metabolite clearance was 0.46 +/- 0.60 ml min-1 kg-1, the elimination half-life was 11.1 +/- 11.3 h and the volume of distribution was 0.55 +/- 1.13 l kg-1. M6G metabolite clearance was 0.71 +/- 0.36 ml min-1 kg-1, the elimination half-life was 18.2 +/- 13.6 h and the volume of distribution was 1.03 +/- 0.88 l kg-1. 5. No significant effect of the loading dose (50 micrograms kg-1 or 200 micrograms kg-1) on the plasma morphine or metabolite concentrations or their derived pharmacokinetic parameters was found. 6. We were unable to identify correlations between gestational age of the infants and any of the determined pharmacokinetic parameters. 7. M3G: morphine and M6G: morphine steady-state plasma concentration ratios were 11.0 +/- 10.8 and 0.8 +/- 0.8, respectively. 8. The metabolism of morphine in neonates, in terms of the respective contributions of each glucuronide pathway, was similar to that in adults.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799518      PMCID: PMC2042627          DOI: 10.1046/j.1365-2125.1996.03539.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

Review 1.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

2.  Can we use methadone for analgesia in neonates?

Authors:  S K Chana; K J Anand
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-09       Impact factor: 5.747

3.  Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.

Authors:  Fei Tang; Henrietta Bada; Chee M Ng; Markos Leggas
Journal:  Biomed Chromatogr       Date:  2019-03-20       Impact factor: 1.902

Review 4.  Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?

Authors:  Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

5.  Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?

Authors:  Iftekhar Mahmood
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

Review 6.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

7.  Morphine glucuronidation in preterm neonates, infants and children younger than 3 years.

Authors:  Catherijne A J Knibbe; Elke H J Krekels; Johannes N van den Anker; Joost DeJongh; Gijs W E Santen; Monique van Dijk; Sinno H P Simons; Richard A van Lingen; Evelyne M Jacqz-Aigrain; Meindert Danhof; Dick Tibboel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.

Authors:  Iftekhar Mahmood
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-02-12       Impact factor: 2.441

9.  Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure.

Authors:  Jason R Wiles; Barbara Isemann; Laura P Ward; Alexander A Vinks; Henry Akinbi
Journal:  J Pediatr       Date:  2014-06-16       Impact factor: 4.406

10.  Pharmacokinetic models of morphine and its metabolites in neonates:: Systematic comparisons of models from the literature, and development of a new meta-model.

Authors:  Katrine Rørbæk Knøsgaard; David John Richard Foster; Mads Kreilgaard; Eva Sverrisdóttir; Richard Neil Upton; Johannes N van den Anker
Journal:  Eur J Pharm Sci       Date:  2016-07-01       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.